---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-116903"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:33:53.802587+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cyclacel Q3 net loss $2.0M, cash $3.0M; Nasdaq extension to Dec 24; going concern doubt

## Summary
- Net loss $2.0M for Q3 2024 vs $6.0M a year ago; cash $3.0M as of Sept 30, 2024.
- R&D expenses fell to $1.0M from $5.2M; fadraciclib R&D $0.9M vs $3.6M.
- Nasdaq granted extension to Dec 24, 2024 to regain minimum stockholders' equity compliance.
- Substantial doubt about going concern; may curtail operations or file for bankruptcy if funding not secured.
- Initial safety/efficacy data from 12 patients in fadraciclib Phase 2 cohort presented at Triple Meeting.

## SEC filing metadata
- accession: 0001104659-24-116903
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000110465924116903/0001104659-24-116903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000110465924116903/tm2428051d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-116903
- JSON: https://secwatch.observer/filing/0001104659-24-116903.json
- Plain text: https://secwatch.observer/filing/0001104659-24-116903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.